4 active not recruiting, 1 recruiting, 1 withdrawn. 6 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 4, Recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Fallopian Tube Endometrioid Adenocarcinoma: new trials by email Literature Review of Recurrent Fallopian Tube Endometrioid Adenocarcinoma trials Research Report on Recurrent Fallopian Tube Endometrioid Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-06-30 | 2023-09-26 | |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
| Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 61 | 2019-12-04 | 2026-08-26 |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, Bevacizumab, Computed Tomography - Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 444 | 2017-06-23 | 2026-10-22 |
Fallopian Tube Neoplasms (4) · Ovarian Neoplasms (3)
Adnexal Diseases (4) · Fallopian Tube Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Neoplasms (4) · Neoplasms by Site (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Gonadal Disorders (3) · Ovarian Diseases (3)
Magnetic Resonance Spectroscopy (4) · Disulfides (3) · Doxorubicin (3) · Immunoglobulin G (3) · Specimen Handling (3) · liposomal doxorubicin (3) · olaparib (3) · Bevacizumab (2) · Paclitaxel (2) · Taxes (2) · Topotecan (2) · pembrolizumab (2) · Biopsy (1) · Blood Component Removal (1) · Contrast Media (1)
National Cancer Institute (NCI) (4) · Mayo Clinic (1) · Roswell Park Cancer Institute (1)
United States (6) · Puerto Rico (2)
Emese Zsiros (1) · Jung-min Lee (1) · Matthew S. Block, MD, PhD (1) · Panagiotis A Konstantinopoulos (1) · Roisin E O'Cearbhaill (1) · Sarah F Adams (1)
U10CA180868 (4), R01CA276313 (1)